Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential laboratory monitoring in autoimmune disease: a matched case-control study from Qatar primary care.

Journal of translational medicine·2026
Same author

Targeted metabolomic profiling of gastric cancer biopsies.

The Indian journal of medical research·2026
Same author

Probabilistic pathways from chronic pain to suicidal ideation in Qatar: a Bayesian-Network study.

Journal of translational medicine·2026
Same author

Tet2 deficiency alters CD4+ T cell function and promotes T cell lymphoma with a TFH cell immunophenotype.

The Journal of experimental medicine·2026
Same author

Real-World Safety and Efficacy of Biosimilar Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer: A Prospective Single-Institution Study From India.

International journal of breast cancer·2026
Same author

Primary Bilateral Breast Rhabdomyosarcoma with Subcutaneous Metastases.

Radiology. Imaging cancer·2026

Related Experiment Video

Updated: Jul 14, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Diffuse Large B-Cell Lymphoma: From Molecular Stratification to Precision Immunotherapy.

Akbar Pasha1, Aayushi Velingkar1, Ramita Sharma1

  • 1Indo-American Cancer Research Foundation, Basavatarakam Indo-American Cancer Hospital and Research Institute, Banjara Hills, Hyderabad 500034, India.

Cells
|July 13, 2026
PubMed
Summary

Advances in profiling technologies are refining the understanding of diffuse large B-cell lymphoma (DLBCL) biology. This leads to dynamic, biology-driven models for personalized treatment selection beyond traditional classification.

Keywords:
cell-of-origin classificationcirculating tumor DNAdiffuse large B-cell lymphomagenomic profilingpersonalized therapytumor microenvironment

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Related Experiment Videos

Last Updated: Jul 14, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Area of Science:

  • Oncology
  • Genetics
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy.
  • Traditional classification and treatment strategies are evolving.

Purpose of the Study:

  • To review how advanced profiling technologies refine DLBCL molecular landscape.
  • To discuss the impact of tumor-intrinsic biology and TME on therapy response.
  • To highlight shifts towards biology-driven personalized therapy.

Main Methods:

  • Genomic, transcriptomic, epigenomic, single-cell, and spatial profiling.
  • Analysis of recurrent chromosomal translocations and tumor-suppressor alterations.
  • Integration of cell-of-origin, genetic subtypes, and immune-cell ecosystems.

Main Results:

  • Refined molecular landscape including oncogenic pathways and TME programs.
  • Identification of biologically distinct subgroups and intratumoral heterogeneity.
  • Clarification of therapy responses to various agents and immunotherapies.

Conclusions:

  • Contemporary DLBCL models incorporate genetic and spatial data beyond COO.
  • Tumor biology and TME are crucial for predicting therapy response.
  • Emerging biomarkers like ctDNA-MRD support personalized treatment strategies.